Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic evidence for efficacy of targeting IL-2, IL-6 and TYK2 signalling in the prevention of type 1 diabetes: a Mendelian randomisation study.

Diabetologia - 1 Dec 2024

Heikkilä Tea E, Kaiser Emilia K, Lin Jake, Gill Dipender, Koskenniemi Jaakko J, Karhunen Ville

Abstract excerpt

AIMS/HYPOTHESIS: We aimed to investigate the genetic evidence that supports the repurposing of drugs already licensed or in clinical phases of development for prevention of type 1 diabetes. METHODS: We obtained genome-wide association study summary statistics for the risk of type 1 diabetes, whole-blood gene expression and serum protein levels and investigated genetic polymorphisms near seven potential drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Mellitus, Type 1
Share to Genome-Wide Association Study

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-2

Share to Interleukin-2 Receptor alpha Subunit

Share to Interleukin-6

Share to Mendelian Randomization Analysis

Share to Receptors, Interleukin-6

Share to TYK2 Kinase

Source

Open in PubMed Open full text

Identifiers

PMID: 39271518
DOI: 10.1007/s00125-024-06267-5
PMCID: PMC11604673

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic evidence for efficacy of targeting IL-2, IL-6 and TYK2 signalling in the prevention of type 1 diabetes: a Mendelian randomisation study.PMID 39271518Read ↗

Genetic evidence for efficacy of targeting IL-2, IL-6, and TYK2 signaling in prevention of type 1 diabetes: A Mendelian randomization studySemantic proximity Read ↗

Exploring the therapeutic potential of interleukin-6 receptor blockade in autoimmune diseases using drug target mendelian randomization.Semantic proximity Read ↗

IL6 receptor inhibitors: exploring the therapeutic potential across multiple diseases through drug target Mendelian randomization.Semantic proximity Read ↗

Based on systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for diabetes.Semantic proximity Read ↗

Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases.Semantic proximity Read ↗

Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes.Semantic proximity Read ↗

Exploration of the causal relationship between inflammatory cytokines and type 2 diabetes via mendelian randomization and polygenic score.Semantic proximity Read ↗

Genetically downregulated interleukin-6 signaling is associated with a favorable cardiometabolic profile: a phenome-wide association studySemantic proximity Read ↗

Differential Associations of Interleukin 6 Receptor Variant Across Genetic Ancestries and Implications for Targeted TherapiesSemantic proximity Read ↗

ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study.Semantic proximity Read ↗

Association of circulating inflammatory proteins with type 2 diabetes mellitus and its complications: a bidirectional Mendelian randomization studySemantic proximity Read ↗

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.